Palatin Technologies (PTN) Capital Expenditures (2012 - 2026)
Palatin Technologies' (PTN) quarterly Capital Expenditures came in at $38483.0 in Q1 2026, up 683.61% quarter-over-quarter from $4911.0 in Q2 2024.
Analysis
Palatin Technologies (PTN) Capital Expenditures (2012 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Capital Expenditures for 11 consecutive years, with $38483.0 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $38483.0; the trailing twelve-month figure through Mar 2026 stood at $43394.0 (up 2.04% YoY), and the FY2024 full-year result was $42526.0, down 90.2% from the prior year.
- Capital Expenditures grew to $38483.0 in Q1 2026 per PTN's latest filing, from $4911.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $141228.0 in Q3 2022 and bottomed at $4911.0 in Q2 2024.
- Historically, Capital Expenditures has averaged $69938.7 across 4 years, with a median of $52396.0 in 2023.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures jumped 3711500.0% in 2022, then slumped 90.63% in 2024.
- Over 4 years, Capital Expenditures stood at $123428.0 in 2022, then sank by 69.52% to $37615.0 in 2023, then slumped by 86.94% to $4911.0 in 2024, then jumped by 683.61% to $38483.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $38483.0, $4911.0, and $37615.0 for Q1 2026, Q2 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 37.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -1.87 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | 38,483.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 38,483.00 |
| Jun 30, 2024 | 4,911.00 |
| Dec 31, 2023 | 37,615.00 |
| Jun 30, 2023 | 52,396.00 |
| Mar 31, 2023 | 116,875.00 |
| Dec 31, 2022 | 123,428.00 |
| Sep 30, 2022 | 141,228.00 |
| Jun 30, 2022 | 37,116.00 |
| Mar 31, 2022 | 77,396.00 |
| Dec 31, 2021 | 89,098.00 |
| Sep 30, 2021 | 57,764.00 |
| Jun 30, 2021 | 1.00 |
| Mar 31, 2021 | 5,721.00 |
| Sep 30, 2019 | 62,880.00 |
| Mar 31, 2019 | 36,139.00 |
| Jun 30, 2018 | 12,951.00 |
| Sep 30, 2017 | 9,500.00 |
| Jun 30, 2017 | 133,403.00 |
| Sep 30, 2015 | 17,695.00 |
| Sep 30, 2013 | 6,239.00 |